BioTuesdays

Tag - CYAD

Celyad Logo
Markets

HCW cuts Celyad Oncology to neutral; removes PT

H.C. Wainwright downgraded Celyad Oncology (NASDAQ:CYAD) to “neutral” from “buy” and removed its price target after the company paused dosing and enrollment in its Phase 1b KEYNOTE-B79 study. Shares of Celyad were...

February 28, 2022
Celyad Logo
Markets

HCW starts Celyad at buy; PT $45

H.C. Wainwright initiated coverage of Celyad (NASDAQ:CYAD) with a “buy” rating and $45 price target, citing the outlook of the company’s pipeline that includes lead candidate, CYAD-01. The stock closed at $30.99...

July 2, 2018